TY - JOUR
T1 - Efficient and reproducible generation of human iPSC-derived cardiomyocytes and cardiac organoids in stirred suspension systems
AU - Prondzynski, Maksymilian
AU - Berkson, Paul
AU - Trembley, Michael A.
AU - Tharani, Yashasvi
AU - Shani, Kevin
AU - Bortolin, Raul H.
AU - Sweat, Mason E.
AU - Mayourian, Joshua
AU - Yucel, Dogacan
AU - Cordoves, Albert M.
AU - Gabbin, Beatrice
AU - Hou, Cuilan
AU - Anyanwu, Nnaemeka J.
AU - Nawar, Farina
AU - Cotton, Justin
AU - Milosh, Joseph
AU - Walker, David
AU - Zhang, Yan
AU - Lu, Fujian
AU - Liu, Xujie
AU - Parker, Kevin Kit
AU - Bezzerides, Vassilios J.
AU - Pu, William T.
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/12
Y1 - 2024/12
N2 - Human iPSC-derived cardiomyocytes (hiPSC-CMs) have proven invaluable for cardiac disease modeling and regeneration. Challenges with quality, inter-batch consistency, cryopreservation and scale remain, reducing experimental reproducibility and clinical translation. Here, we report a robust stirred suspension cardiac differentiation protocol, and we perform extensive morphological and functional characterization of the resulting bioreactor-differentiated iPSC-CMs (bCMs). Across multiple different iPSC lines, the protocol produces 1.2E6/mL bCMs with ~94% purity. bCMs have high viability after cryo-recovery (>90%) and predominantly ventricular identity. Compared to standard monolayer-differentiated CMs, bCMs are more reproducible across batches and have more mature functional properties. The protocol also works with magnetically stirred spinner flasks, which are more economical and scalable than bioreactors. Minor protocol modifications generate cardiac organoids fully in suspension culture. These reproducible, scalable, and resource-efficient approaches to generate iPSC-CMs and organoids will expand their applications, and our benchmark data will enable comparison to cells produced by other cardiac differentiation protocols.
AB - Human iPSC-derived cardiomyocytes (hiPSC-CMs) have proven invaluable for cardiac disease modeling and regeneration. Challenges with quality, inter-batch consistency, cryopreservation and scale remain, reducing experimental reproducibility and clinical translation. Here, we report a robust stirred suspension cardiac differentiation protocol, and we perform extensive morphological and functional characterization of the resulting bioreactor-differentiated iPSC-CMs (bCMs). Across multiple different iPSC lines, the protocol produces 1.2E6/mL bCMs with ~94% purity. bCMs have high viability after cryo-recovery (>90%) and predominantly ventricular identity. Compared to standard monolayer-differentiated CMs, bCMs are more reproducible across batches and have more mature functional properties. The protocol also works with magnetically stirred spinner flasks, which are more economical and scalable than bioreactors. Minor protocol modifications generate cardiac organoids fully in suspension culture. These reproducible, scalable, and resource-efficient approaches to generate iPSC-CMs and organoids will expand their applications, and our benchmark data will enable comparison to cells produced by other cardiac differentiation protocols.
UR - http://www.scopus.com/inward/record.url?scp=85198665614&partnerID=8YFLogxK
U2 - 10.1038/s41467-024-50224-0
DO - 10.1038/s41467-024-50224-0
M3 - Article
AN - SCOPUS:85198665614
SN - 2041-1723
VL - 15
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 5929
ER -